New intranasal corticosteroid

GlaxoSmithKline has launched a new intranasal corticosteroid, Avamys, for the treatment of allergic rhinitis in adults and children over six years old.

Each spray actuation delivers 27.5 micrograms of fluticasone furoate.

View Avamys drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more